

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 June 2008 (05.06.2008)

PCT

(10) International Publication Number
WO 2008/065543 A3

(51) International Patent Classification:

C12N 15/62 (2006.01) *A61K 38/17* (2006.01)
A61K 47/48 (2006.01) *C07K 14/71* (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/IB2007/004354

(22) International Filing Date:

28 November 2007 (28.11.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

06291824.8 28 November 2006 (28.11.2006) EP
07290042.6 11 January 2007 (11.01.2007) EP

(71) Applicant (for all designated States except US): **CENTE-LION** [FR/FR]; 72-92 rue Léon Geffroy, F-94400 Vitry-sur-Seine (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NESBIT, Mark** [GB/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **CAMERON, Béatrice** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **BLANCHE, Francis** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **SORDELLO, Sylvie** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **NICOLAZZI, Céline** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **TROMBE, Marc** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR).

(74) Agent: **BOUVET, Philippe**; sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- the filing date of the international application is within two months from the date of expiration of the priority period

(88) Date of publication of the international search report:
14 August 2008

(54) Title: MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY

(57) Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.



WO 2008/065543 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2007/004354

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K14/47 C12N15/62 C07K14/71 A61K47/48 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/46380 A (CHIRON CORP [US]; KAVANAUGH WILLIAM MICHAEL [US]; BALLINGER MARCUS [US]) 10 August 2000 (2000-08-10) abstract	1-39
X	POWELL ANDREW K ET AL: "Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 32, 9 August 2002 (2002-08-09), pages 28554-28563, XP002429672 ISSN: 0021-9258 the whole document	1-39

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 June 2008

Date of mailing of the international search report

10/06/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Aslund, Fredrik

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2007/004354

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ANDERSON JANE ET AL: "Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand" HUMAN MOLECULAR GENETICS, vol. 7, no. 9, September 1998 (1998-09), pages 1475-1483, XP002429673 ISSN: 0964-6906 page 1480 - page 1481 -----	1-39
A	DUCHESNE LAURENCE ET AL: "N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 37, September 2006 (2006-09), pages 27178-27189, XP002429674 ISSN: 0021-9258 abstract; figure 2 -----	
A	TRUEB BEAT ET AL: "Characterization of FGFR1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 36, 5 September 2003 (2003-09-05), pages 33857-33865, XP002429675 ISSN: 0021-9258 -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2007/004354

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0046380 A	10-08-2000	AU 3224700 A	25-08-2000